Fidson Healthcare to Produce Generic Influenza Treatment

Fidson Healthcare Plc has been selected as one of eleven manufacturers across nine countries to enter sublicensing agreements with the Medicines Patent Pool (MPP) for the development and manufacture of generic versions of baloxavir marboxil, an antiviral treatment for influenza. This initiative is part of MPP’s voluntary licensing agreement with Roche.

Charles Gore, Executive Director of MPP, emphasized the importance of this collaboration in preparing for health emergencies. The focus will be on supporting product development and regulatory approval to ensure the rapid availability of quality-assured generic baloxavir.

Tamara Schudel, Vice President and Head of Global Policy at Roche, noted that this transition from agreement to actual sublicensing marks a significant milestone. Biola Adebayo, Managing Director and CEO of Fidson Healthcare, expressed that being chosen as a sublicensee validates Fidson’s commitment to quality pharmaceutical manufacturing and improving healthcare outcomes.